NPM1 and acute myeloid leukemia: These subgroup analyses were not relevant in the ALFA-0701 trial since the prognostic impact of NPM1 mutated/FLT3–ITD negative genotype was not significant in the whole CN-AML cohort, but only in CN-AML patients treated in the control arm.